Chiasma Strengthens Management Team with Announcement of Chief Financial Officer

Biotechnology Industry Veteran Mark J. Fitzpatrick to Join Chiasma NEWTON, Mass. and JERUSALEM, May 18, 2015 /PRNewswire/ — Chiasma, Inc., a U.S. privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced the appointment of Mark J. Fitzpatrick as the company’s chief financial officer, by June 10, 2015. “Bringing on Mark as…